Literature DB >> 12447730

Hepatitis C virus seroconversion among young injection drug users: relationships and risks.

Judith A Hahn1, Kimberly Page-Shafer, Paula J Lum, Philippe Bourgois, Ellen Stein, Jennifer L Evans, Michael P Busch, Leslie H Tobler, Bruce Phelps, Andrew R Moss.   

Abstract

The present study examined reasons for the high incidence of hepatitis C virus (HCV) infection among young injection drug users (IDUs). IDUs <30 years old who tested negative for HCV antibody were enrolled in a prospective cohort. Risk factors for seroconversion were examined using time-dependent regression analyses: 48 of 195 IDUs seroconverted to HCV, for an incidence rate of 25.1/100 person-years (95% confidence interval, 18.7-32.9/100 person-years). Independent risk factors included sharing needles with an HCV-infected sex partner (borderline statistical significance, P=.11) or a person who was not a sex partner, sharing nonsterile drug-preparation equipment, pooling money with another IDU to buy drugs, and exchanging sex for money. Ubiquitous behaviors among young IDUs, such as the forming of injecting or sexual partnerships and consequent sharing of needles and drug preparation equipment, are risk factors for HCV. Interventions to reduce HCV transmission must recognize the importance of relationships on injecting risk.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12447730     DOI: 10.1086/345554

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  139 in total

Review 1.  Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment.

Authors:  Enrique R Pouget; Holly Hagan; Don C Des Jarlais
Journal:  Addiction       Date:  2012-04-17       Impact factor: 6.526

2.  Injecting risk behavior among traveling young injection drug users: travel partner and city characteristics.

Authors:  Martha E Montgomery; Robin S Fatch; Jennifer L Evans; Michelle Yu; Peter J Davidson; Kimberly Page; Judith A Hahn
Journal:  J Urban Health       Date:  2013-06       Impact factor: 3.671

Review 3.  The provision of non-needle/syringe drug injecting paraphernalia in the primary prevention of HCV among IDU: a systematic review.

Authors:  Michelle Gillies; Norah Palmateer; Sharon Hutchinson; Syed Ahmed; Avril Taylor; David Goldberg
Journal:  BMC Public Health       Date:  2010-11-23       Impact factor: 3.295

4.  Cessation of injecting drug use among street-based youth.

Authors:  Colin Steensma; Jean-François Boivin; Lucie Blais; Elise Roy
Journal:  J Urban Health       Date:  2005-09-29       Impact factor: 3.671

5.  Injection drug users: the overlooked core of the hepatitis C epidemic.

Authors:  Brian R Edlin; Michael R Carden
Journal:  Clin Infect Dis       Date:  2006-01-20       Impact factor: 9.079

6.  A syringe exchange programme in prison as prevention strategy against HIV infection and hepatitis B and C in Berlin, Germany.

Authors:  K Stark; U Herrmann; S Ehrhardt; U Bienzle
Journal:  Epidemiol Infect       Date:  2005-12-22       Impact factor: 2.451

7.  Injecting alone among young adult IDUs in five US cities: evidence of low rates of injection risk behavior.

Authors:  Holly Hagan; Jennifer V Campbell; Hanne Thiede; Steffanie A Strathdee; Lawrence Ouellet; Mary Latka; Sharon Hudson; Richard S Garfein
Journal:  Drug Alcohol Depend       Date:  2007-03-23       Impact factor: 4.492

8.  Integrating viral hepatitis prevention into public health programs serving people at high risk for infection: good public health.

Authors:  Joanna Buffington; T Stephen Jones
Journal:  Public Health Rep       Date:  2007       Impact factor: 2.792

9.  Traveling young injection drug users at high risk for acquisition and transmission of viral infections.

Authors:  Judith A Hahn; Kimberly Page-Shafer; Jamye Ford; Alan Paciorek; Paula J Lum
Journal:  Drug Alcohol Depend       Date:  2007-11-05       Impact factor: 4.492

10.  Risk of hepatitis C virus transmission through drug preparation equipment: a systematic and methodological review.

Authors:  P De; E Roy; J-F Boivin; J Cox; C Morissette
Journal:  J Viral Hepat       Date:  2008-01-20       Impact factor: 3.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.